LongeVC portfolio company Constructive Bio has announced a collaboration with the Ellison Institute of Technology at Oxford to accelerate innovation in synthetic genomics and engineering biology. The partnership will combine Constructive Bio's synthetic genome platform with EIT Oxford's research infrastructure to advance new medicines, disease-resistant cells, and sustainable materials.
The collaboration brings together shared scientific leadership, with Professor Jason Chin serving as both Constructive Bio's Chief Scientific Officer and Founding Director of EIT's Generative Biology Institute. Constructive Bio's platform reprograms cells to create next-generation therapeutics with enhanced properties. At the same time, EIT's institute will host over 300 researchers at the Oxford Science Park focused on making biology engineerable, from therapeutic molecules to climate-resilient crops.
We're proud to support CEO Aleksandra Wlodek and the Constructive Bio team as they advance the future of synthetic biology.
Read the full story by Chris Marshall in The Times here.
The collaboration brings together shared scientific leadership, with Professor Jason Chin serving as both Constructive Bio's Chief Scientific Officer and Founding Director of EIT's Generative Biology Institute. Constructive Bio's platform reprograms cells to create next-generation therapeutics with enhanced properties. At the same time, EIT's institute will host over 300 researchers at the Oxford Science Park focused on making biology engineerable, from therapeutic molecules to climate-resilient crops.
We're proud to support CEO Aleksandra Wlodek and the Constructive Bio team as they advance the future of synthetic biology.
Read the full story by Chris Marshall in The Times here.